Parenteral Formulations of Kinase Inhibitors Using Cyclodextrin Mediators

The patent employs cyclodextrin complexes as intermediary carriers to solubilize and stabilize the hydrophobic kinase inhibitor compounds. The cyclodextrin forms inclusion complexes with the hydrophobic compounds, acting as a mediator that enables their stable formulation in aqueous parenteral solutions while maintaining their therapeutic activity against receptor tyrosine kinases.

The invention creates composite formulation systems combining cyclodextrin polymers with hydrophobic kinase inhibitor compounds. This composite approach allows the hydrophobic drug molecules to be incorporated into the cyclodextrin structure, achieving both solubility and stability in parenteral formulations while preserving the therapeutic efficacy needed to inhibit receptor tyrosine kinase pathways.

Cyclodextrin complexes serve as intermediary carriers that enable parenteral administration of hydrophobic compounds. The cyclodextrin forms water-soluble inclusion complexes with the hydrophobic kinase inhibitors, making them suitable for intravenous and other parenteral routes while maintaining the therapeutic activity required to inhibit cancer cell proliferation.

The patent changes the physical-chemical parameters of the formulation by using cyclodextrin complexes to alter solubility and stability characteristics. This parameter change enables the hydrophobic compounds to be administered parenterally, transforming them from difficult-to-administer to easily administrable while preserving their anti-proliferative activity.

Cyclodextrin complexes act as intermediary carriers that accommodate the hydrophobic kinase cascade inhibitors with high selectivity. The cyclodextrin structure provides a stable environment for these selective compounds, enabling their formulation while preserving their ability to specifically inhibit the Ras/Raf/MEK/ERK pathway in proliferative disorders.

The invention develops composite formulation systems using cyclodextrin polymers combined with selective kinase cascade inhibitors. This composite approach maintains the high selectivity needed for targeting proliferative disorders while providing the stability required for parenteral administration and storage.